Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s whyMaking GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars. The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement Read More
New evidence shows tirzepatide and semaglutide strongly protect the heartNew evidence shows tirzepatide and semaglutide strongly protect the heart
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs. A massive real-world study comparing tirzepatide and Read More
Why some people are microdosing GLP-1Why some people are microdosing GLP-1
NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications. NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications.
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in ValueEli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone. The 150-year-old drugmaker is the first company in health care to hit the milestone.
Opinion: Trump’s regressive deal on GLP-1s misses the mark for patients like meOpinion: Trump’s regressive deal on GLP-1s misses the mark for patients like me
The U.S. government is finally flexing its negotiating muscle to reduce GLP-1 prices and expand access to these medicines — for weight loss — in federal health programs. President Trump’s much-anticipated “deal” with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the Read More
Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapyQ&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy
People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in their health, such as improved blood sugar, lower blood pressure and weight loss. People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in Read More
I Was a 34-Year-Old New Mom When I Was Diagnosed With Stage IV Breast CancerI Was a 34-Year-Old New Mom When I Was Diagnosed With Stage IV Breast Cancer
WeGotThis.org founder and author Elissa Kalver wants to reframe the conversation around metastatic breast cancer.
Novo Nordisk rolls out lower prices for Ozempic and WegovyNovo Nordisk rolls out lower prices for Ozempic and Wegovy
People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
How GLP-1s impact the heart and kidneys of veterans with type 2 diabetesHow GLP-1s impact the heart and kidneys of veterans with type 2 diabetes
Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects. Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in Read More
Olivia Munn Meets Breast Cancer Patient Inspired by Her JourneyOlivia Munn Meets Breast Cancer Patient Inspired by Her Journey
Over the past year and a half, Olivia Munn has shared her journey with breast cancer, inspiring women to get screened. TODAY’s Jenna Bush Hager introduces her to Michaela Del Barrio, a woman who is navigating a cancer journey similar to Munn’s.